Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701616 | Journal of Thoracic Oncology | 2017 | 27 Pages |
Abstract
The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p = 0.24 for PFS and 0.45 for OS, stratified by study).
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Solange MD, PhD, Rolf A. MD, Urania ScD, Santiago MD, Bartomeu MD, Oliver MD, Linda MD, Ana MD, PhD, Robbert MD, Thierry MD, PhD, Peter MD, PhD, Manuel MD, Javier MD, Alessandra MD, Daniel MD, Michael T. MD, Sinead MD, Bonne MD, PhD, Egbert F. MD, PhD,